Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Tranexamic acid (Primary)
- Indications Gastrointestinal disorders; Post-surgical adhesions; Postoperative ileus
- Focus Proof of concept; Therapeutic Use
- Acronyms PROFILE
- Sponsors Leading BioSciences; Palisade Bio
- 09 Aug 2023 According to a Palisade Bio media release, primary endpoint (Change from baseline in extent and severity of intra-abdominal adhesions among subjects treated with LB1148 or placebo) has not been met.
- 09 Aug 2023 Topline results presented in Palisade Bio media release.
- 24 May 2023 According to a Palisade Bio media release, the company expects to report topline data from this study within four weeks following the last surgery.